Ask AI
ProCE Banner Activity

Expert Strategies for Improving Heart Failure Care With GDMT, Specialist Referral, and SGLT2 Inhibitors

Clinical Thought

Learn about specific considerations for implementing guideline-directed medical therapy for all patients with heart failure, including the red flags that mark disease progression and warrant a referral to a specialist as well as strategies for improving clinical inertia in prescribing SGLT2 inhibitors.

Released: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This educational activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with heart failure.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the clinical symptoms of heart failure (HF) and analyze the role of established and emerging cardiac biomarkers in its early identification and management

  • Evaluate the efficacy, safety, and cardiovascular benefits of early and sustained SGLT2 inhibitor use in heart failure treatment

  • Apply practical strategies to integrate SGLT2 inhibitors into personalized care plans for patients with heart failure across the spectrum on left ventricular ejection fraction